K
Keiji Fukuda
Researcher at Li Ka Shing Faculty of Medicine, University of Hong Kong
Publications - 99
Citations - 29021
Keiji Fukuda is an academic researcher from Li Ka Shing Faculty of Medicine, University of Hong Kong. The author has contributed to research in topics: Influenza A virus subtype H5N1 & Influenza A virus. The author has an hindex of 46, co-authored 95 publications receiving 27831 citations. Previous affiliations of Keiji Fukuda include United States Department of Agriculture & University of Hong Kong.
Papers
More filters
Journal Article
Retroviral risk factors in patients with autoimmune disease.
Barbara E. Drevlow,Ellen M. Schilling,Rima F. Khabbaz,Jonathan E. Kaplan,Keiji Fukuda,James M. Sinacore,Rosalind Ramsey-Goldman +6 more
TL;DR: Self-reported retroviral risk factors were generally not increased in patients with autoimmune disease compared to healthy controls; the role of exogenous retroviruses in the pathogenesis of SLE and RA remains unclear.
Journal ArticleDOI
Influenza Surveillance with Rapid Diagnostic Tests
TL;DR: This work has shown a clear relationship between the prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C infection and the RT-PCR status and mode of acquisition and the 2-5A synthetase/ RNase L antiviral pathway associated with chronic fatigue syndrome.
Journal ArticleDOI
Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC): Supporting the transition from strategy to action
Keiji Fukuda,Direk Limmathurotsakul,Iruka N. Okeke,Nandini Shetty,Rogier van Doorn,Nicholas A. Feasey,Francesca Chiara,Ghada Zoubiane,Tim Jinks,Julian Parkhill,Jean B. Patel,Stuart Reid,Alison Holmes,Sharon J. Peacock,Surveillance +14 more
TL;DR: A new international expert group SEDRIC (Surveillance and Epidemiology of Drug Resistant Infections Consortium) is brought together to advance and transform the ways of tracking, sharing and analysing rates of infection and antimicrobial resistance, burden of disease, information on antimicrobial use, opportunities for preventative measures such as vaccines, and contamination of the environment.
Journal ArticleDOI
Emergence of novel coronavirus: global context.
TL;DR: The novel coronavirus (nCoV) discovered in 2012 adds another such disease to the list of infectious diseases and its potential impact may best be understood in such a historic and global context.